Citi Reports Uneventful 4Q For Isis Pharmaceuticals

According to Citi, Isis Pharmaceuticals (NASDAQ: ISIS) had an uneventful 4Q.

Citi said that ISIS reported total revenues of $26.4M, higher than our estimate of $25.1M and consensus estimate of $22.6M. “EPS for 4Q came in at ($0.14), comparing to our and Street estimates of ($0.13) and ($0.22) respectively. As of December 31, 2010 Co had cash and cash equivalents of $475M.”

Isis Pharmaceuticals closed yesterday at $9.12.